藥明康德(603259.SH):業績新高下預計2023年收入至413~421億元,經調整non-IFRS毛利同比增長12-14%
格隆匯3月20日丨藥明康德(603259.SH)公佈2022年年度報吿,2022年公司實現營業收入393.55億元,創紀錄的業績增長71.84%;歸屬於上市公司股東的淨利潤88.14億元,同比增長72.91%;歸屬於上市公司股東的扣除非經常性損益的淨利潤82.60億元,同比增長103.27%;基本每股收益3.01元;擬每10股派發現金紅利人民幣8.9266元(含税)。
在2022年強勁增長基礎上,公司預計2023年收入將繼續增長5-7%。其中,剔除特定商業化項目,WuXi Chemistry收入預計增長36-38%,且TIDES(WuXi Chemistry中新分子業務)預計增速為WuXi Chemistry整體增速的近2倍;其他業務板塊(WuXiTesting,WuXiBiology,WuXiATU)收入預計增長20-23%。
報吿期內,公司實現毛利人民幣146.78億元,較2021年同期增長76.62%;其中主營業務毛利人民幣146.62億元,毛利率37.29%,較去年同期提升1.02個百分點。
2023年公司將持續提升經營效率,推動利潤和自由現金流增長。公司預計經調整non-IFRS毛利同比增長12-14%,同時隨着經營效率進一步提升,將有助於經調整non-IFRS淨利潤的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.